| $337M | ||
| $259M | ||
| $100M | ||
| $79M | ||
| $60M | ||
| $58M |
Buys | $447,931 | 5 | 100 |
Sells | $0 | 0 | 0 |
| Ramachandra Sumant | director | 1 | $115,220 | 0 | $0 | $115,220 |
| Newton Charles W. | Chief Financial Officer | 1 | $111,620 | 0 | $0 | $111,620 |
| Seely Lynn | President and CEO | 1 | $106,190 | 0 | $0 | $106,190 |
| Klausner Richard | director | 1 | $94,942 | 0 | $0 | $94,942 |
| BRAWLEY OTIS W | director | 1 | $19,958 | 0 | $0 | $19,958 |
Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate population of T cells with durable stemness. Its pipeline includes LYL797, a T cell product candidate for the treatment of non-small cell lung cancer and triple negative breast cancers; LYL845, that targets multiple solid tumors; and NY-ESO-1 for synovial sarcoma and other solid tumor indications. The company entered into research and development collaboration and license agreement with GlaxoSmithKline for NY-ESO-1 program. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
Over the last 12 months, insiders at Lyell Immunopharma, Inc. have bought $447,931 and sold $0 worth of Lyell Immunopharma, Inc. stock.
On average, over the past 5 years, insiders at Lyell Immunopharma, Inc. have bought $373,973 and sold $132,286 worth of stock each year.
Highest buying activity among insiders over the last 12 months: Ramachandra Sumant (director) — $115,220. Newton Charles W. (Chief Financial Officer) — $111,620. Seely Lynn (President and CEO) — $106,190.
The last purchase of 35,640 shares for transaction amount of $19,958 was made by BRAWLEY OTIS W (director) on 2025‑03‑31.
| 2025-03-31 | BRAWLEY OTIS W | director | 35,640 0.0126% | $0.56 | $19,958 | -12.64% | ||
| 2025-03-21 | Ramachandra Sumant | director | 200,000 0.0675% | $0.58 | $115,220 | -16.28% | ||
| 2025-03-17 | Newton Charles W. | Chief Financial Officer | 200,000 0.0731% | $0.56 | $111,620 | -1.86% | ||
| 2025-03-14 | Klausner Richard | director | 158,000 0.0549% | $0.60 | $94,942 | -12.49% | ||
| 2025-03-14 | Seely Lynn | President and CEO | 175,000 0.0614% | $0.61 | $106,190 | -12.49% | ||
| 2023-08-15 | Sale | Klausner Richard | director | 58,020 0.0231% | $2.28 | $132,286 | -12.23% | |
| 2021-06-21 | FRIEDMAN CATHY | director | 17,648 0.0422% | $17.00 | $300,016 | -50.33% |
| Klausner Richard | director | 843365 5.6953% | $7.79M | 1 | 1 | |
| Seely Lynn | President and CEO | 712500 4.8116% | $6.58M | 1 | 0 | |
| Ramachandra Sumant | director | 200000 1.3506% | $1.85M | 1 | 0 | |
| Newton Charles W. | Chief Financial Officer | 200000 1.3506% | $1.85M | 1 | 0 | |
| BRAWLEY OTIS W | director | 35640 0.2407% | $329,313.60 | 1 | 0 | |
| FRIEDMAN CATHY | director | 17648 0.1192% | $163,067.52 | 1 | 0 | <0.0001% |
$5,558,275 | 76 | -5.88% | $154.94M | |
$48,218,096 | 42 | 0.89% | $125.2M | |
$18,752,549 | 33 | -28.39% | $148.62M | |
$294,424,120 | 20 | 1.33% | $129.54M | |
$1,351,643 | 19 | 46.45% | $142.67M | |
$111,692,551 | 18 | 13.51% | $142.68M | |
$448,999,793 | 15 | -19.99% | $135.53M | |
$10,143,329 | 12 | 11.84% | $161.18M | |
$73,968,137 | 12 | -34.52% | $135.06M | |
$9,999,920 | 10 | -40.03% | $128.37M | |
$1,073,250 | 10 | 19.46% | $125.66M | |
$13,043,783 | 8 | 732.82% | $150.2M | |
$22,090,972 | 7 | -3.49% | $132.51M | |
$478,647 | 7 | 69.41% | $124.34M | |
$63,981 | 5 | -11.55% | $136.79M | |
$32,289,200 | 3 | -5.46% | $158.99M | |
$9,999,990 | 2 | 25.53% | $137.77M | |
Lyell Immunopharma, Inc. (LYEL) | $300,016 | 1 | -50.33% | $136.83M |
$5,512,500 | 1 | -7.91% | $139.97M |
| Increased Positions | 37 | +28.24% | 620,652 | +8.19% |
| Decreased Positions | 48 | -36.64% | 534,048 | -7.04% |
| New Positions | 15 | New | 54,524 | New |
| Sold Out Positions | 10 | Sold Out | 178,581 | Sold Out |
| Total Postitions | 120 | -8.4% | 8M | +1.14% |
| Mwg Management Ltd. | $9,295.00 | 6.84% | 20.16M | 0 | 0% | 2024-12-31 |
| Orland Properties Ltd | $6,958.00 | 5.12% | 15.09M | 0 | 0% | 2024-12-31 |
| Blackrock, Inc. | $5,865.00 | 4.31% | 12.72M | -544,298 | -4.1% | 2025-03-31 |
| Decheng Capital Llc | $5,490.00 | 4.04% | 11.91M | +12M | New | 2024-12-31 |
| Vanguard Group Inc | $4,502.00 | 3.31% | 9.77M | -305,399 | -3.03% | 2024-12-31 |
| Foresite Capital Management Iv, Llc | $3,838.00 | 2.82% | 8.32M | 0 | 0% | 2024-12-31 |
| Foresite Capital Management V, Llc | $3,749.00 | 2.76% | 8.13M | +8M | New | 2024-12-31 |
| Wuxi Apptec Co., Ltd. | $3,407.00 | 2.51% | 7.39M | -291,446 | -3.79% | 2024-09-30 |
| Venbio Partners Llc | $3,274.00 | 2.41% | 7.1M | +7M | New | 2024-12-31 |
| Price T Rowe Associates Inc /Md/ | $3,186.00 | 2.34% | 6.91M | -441,528 | -6% | 2024-12-31 |